Funding

Cyllene Therapeutics

France · Biotech · Enterprise software

Develops DNA medicines for severe neurogenic bladder conditions and other neurological diseases

Visit cyllene-tx.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series C€33MBpifrance Investissement — Role not disclosedGordonMD Global Investments — Role not disclosedLamond Ventures — Role not disclosedMerck Ventures B.V. — Role not disclosedT. Andera Partners SAS — Role not disclosed

Investors

Bpifrance InvestissementSeries CGordonMD Global InvestmentsSeries CLamond VenturesSeries CMerck Ventures B.V.Series CT. Andera Partners SASSeries C

Coverage

Jul 7, 2026Cyllene Therapeutics · Series C

Similar companies

Knowledge WorkTokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.¥4.8B · Series C debt second close
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
Sourcescyllene-tx.com ↗